

ASX ANNOUNCEMENT

Dr Jenn King joins Exopharm Board

31 August 2021, Melbourne, Australia: Exosome medicine company Exopharm Limited (ASX: EX1) is pleased to announce the appointment of Dr Jennifer (Jenn) King to the Exopharm Board, effective 1 September 2021.

Dr King joins the Company's Board as an independent Non-executive Director, and will continue in her role as a member of the Company's Advisory Panel under her existing terms of appointment to the Panel.

Jenn has experience in Pharmaceuticals and Biotechnology, having been Director, New Product Marketing in Shire Human Genetic Therapies, Senior Director Business Development & Licensing of Shire Pharmaceuticals supporting the rare disease business unit. More recently Jenn served as the Senior Vice President, Business Development of Intellia Therapeutics Inc., a pioneering company focused on the development of CRISPR/Cas9 genome editing therapies for patients with severe diseases.

Earlier in her career Jenn worked at Millennium Pharmaceuticals and studied at Massachusetts Institute of Technology (Bachelor of Science), Stanford University School of Medicine (PhD) and Northeastern University (MBA).

Jenn has particular knowledge and insights relevant to Exopharm. She has been involved in the emergence of nucleic acid medicines (DNA and RNA) within both Pharma and Biotech. With an extensive professional network in North America, Jenn currently works as an independent consultant to a select group of emerging international biotechnology companies.

Exopharm's Founder and CEO Dr Ian Dixon said "Dr Jenn King brings to the Board of Exopharm a wealth of knowledge and networks at an important stage in our progress. As a champion of advanced medicines, Jenn will help guide us as we select and develop products of our own. Jenn is also helping us navigate the challenges of business development, partnering and licensing. Jenn sees that Exopharm can harness exosomes as an improved way to deliver variations of nucleic acid medicines to treat important genetic and other conditions."

Dr King said "I can see clearly how Exopharm can build financial value with its exosome technologies and products, and tackle a myriad of genetic and other conditions with the improved delivery of nucleic acid medicines using exosomes. I like that Exopharm thinks big. As a Board member I will help Exopharm focus and prioritise its high-value assets to achieve this vision."

By the Board - this announcement has been authorised for release by the board.

Company and Media Enquiries:

Join our mailing list to receive updates:

<mailto:info@exopharm.com><http://exo.ph/ExoMails>

www.exopharm.com

P: +61 (0)3 9111 0026

Rudi Michelson
Monsoon Communications
Tel: +61 (0)3 9620 3333

ABOUT EXOPHARM

Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative medicines and generate revenue from multiple partnership deals.

Exosomes are seen by the Biopharma industry as a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins – part of the global market for drug delivery systems which is growing at a compound annual growth rate (CAGR) of 5% and valued at around US\$170 billion in 2021.

For some medicines, exosomes are an alternative and superior means for delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell penetrating peptides, viral vectors and liposomes.

Exopharm's LEAP technology solves the challenge of purifying clinical-grade exosomes at large scale and low cost.

Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.

Exopharm uses variations and combinations of LOAD and EVPS to enable its Biopharma partners to improve delivery of their drug candidates and help them design and test new exosome medicines aimed at treating a wide scope of medical problems including neurological disease, infectious disease, cancer, and fibrosis.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.